- Details
- In this Society of Nuclear Medicine and Molecular Imaging- Special Session during the 2021 LUGPA CME presentations, Dr Steven Rowe discusses a number of different scenarios that we might encounter clinically where conventional imaging is clearly being replaced by PSMA based imaging. In the last part of his talk, Dr. Rowe focuses on some future directions where PSMA PET may have some interesting th...
|
- Details
- In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Jeremie Calais presents on understanding the physiological PSMA biodistribution and the pathological uptake of the use of PSMA for prostate cancer. Independent Medical Education Initiative Supported by Novartis/Adacap and Point Biopharma Biographies: Jeremie Calais, MD, MSc, Director, Clinical Research Pro...
|
- Details
- In a conversation hosted by Phillip Koo, Sam Mehr outlines the intricacies of establishing a theranostics program within a medical oncology practice. Dr. Mehr discusses the "NCS/Nebraska Cancer Specialists model," which aims to offer targeted nuclear therapy through a patient-centered approach. He emphasizes the importance of a multidisciplinary team, including a program director who serves as the...
|
- Details
- The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed, and t...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen discuss the Clinical Cancer Research publication on the results from the CONDOR Phase 3, multicenter study. In particular, conventional imaging performs poorly when PSA levels are low, less than 2 ng/mL, and the use of novel PET radiotracers may address this issue and provide more sensitive imaging. CONDOR was a prospective stu...
|
- Details
- Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...
|
- Details
- On December 1, 2020, the US Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) for use for patients with suspected prostate cancer metastasis in UCLA and UCSF. It is the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In a follow-up conversation after speaking about the approv...
|
- Details
- Jeremie Calais, MD, MSc, joins Phillip Koo, MD, FACS, to discuss the approval of Gallium 68 PSMA-11, the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The safety and efficacy of Ga 68 PSMA-11 were evaluated in two prospective clinical trials, which lead to the United States Federal Drug Administ...
|
- Details
- 68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was FDA approved on December 1, 2020. The approval was granted to the University of California–San Francisco (UCSF) and UC–Los Angeles (UCLA). 68 Ga-PSMA-11 is indicated for suspected metastatic disease at the time of initial staging prior to definitive ther...
|
- Details
- Prostate Cancer Outreach Webinar - Hosted by The Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Prostate Cancer Working Group, and faculty from the University of California, San Francisco (UCSF) Molecular imaging and radionuclide therapies play an important role in the management of patients with prostate cancer. Recent advances are allowing for increased precision in both diagnosis a...
|
